Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers

NCT04913220 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04913220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04913220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Terminated
Start date
July 15, 2021
Completion date
February 18, 2025
Enrollment
46 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, squamous cell carcinoma of skin